胰腺癌分子靶向治疗的研究进展

许莹; 戴树龙

doi:10.3969/j.issn.1001-5256.2016.10.048

胰腺癌分子靶向治疗的研究进展

DOI: 10.3969/j.issn.1001-5256.2016.10.048

许莹,
戴树龙

1. 南京医科大学附属淮安第一医院消化科
2. 浙江省德清县人民医院外科

详细信息

中图分类号: R735.9
计量
- 文章访问数: 1507
- HTML全文浏览量: 15
- PDF下载量: 376
- 被引次数: 0
出版历程
- 出版日期: 2016-10-20

Research advances in molecular targeted therapy for pancreatic cancer

Department of Gastroenterology, Huaian First Hospital Affiliated to Nanjing Medical University

摘要

摘要:
胰腺癌是预后最差的恶性肿瘤之一,发病与西方化饮食、吸烟、饮酒、肥胖、慢性胰腺炎及胰腺癌家族史等因素有关。目前,胰腺癌的治疗以手术及化疗为主,但疗效并不理想,了解胰腺癌发病的具体分子机制能更好的预防和治疗胰腺癌。介绍了胰腺癌发病的具体分子机制及其靶向治疗的最新进展。认为在传统治疗的基础上辅以分子靶向药物治疗有助于改善胰腺癌患者的预后。
- 胰腺肿瘤 /
- 靶向治疗 /
- 综述
Abstract:
Pancreatic cancer remains one of the malignant tumors with the worst prognosis,and its incidence is associated with Western diet,smoking,drinking,obesity,chronic pancreatitis,and a family history of pancreatic cancer. Currently,the treatment of pancreatic cancer focuses on surgery and chemotherapy,but no ideal therapeutic effect has been achieved. An understanding of the specific molecular mechanism of the development of pancreatic cancer helps to better prevent and treat pancreatic cancer. This article introduces the latest advances in the specific molecular mechanism of the development of pancreatic cancer and its targeted therapy and points out that molecular-targeted therapy in addition to traditional treatment helps to improve the prognosis of patients with pancreatic cancer.
- pancreatic neoplasms /
- targeted therapy /
- review

HTML全文

参考文献(22)

[1]American Cancer Society.Cancer facts and figures 2015[Z].USA:American Cancer Society(ACS):Atlanta,2015.

[2]MAMON HJ,NIEDZWIECKI D,HOLLIS DA,et al.Phase 2 trial of gemcitabine,5-florouracil,and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma:Cancer and Leukemia Group B(CALGB)80003[J].Cancer,2011,117(12):2620-2628.

[3]KLEEFF J,KORC M,APTE M,et al.Pancreatic cancer[J].Nat Rev Dis Primers,2016.[Epub ahead of print].

[4]KARANDISH F,MALLIK S.Biomarkers and targeted therapy in pancreatic cancer[J].Biomark Cancer,2016.[Epub ahead of print].

[5]GOPINATHAN A,MORTON JP,JODRELL DI,et al.GEMMs as preclinical models for testing pancreatic cancer therapies[J].Dis Model Mech,2015,8(10):1185-1200.

[6]LEE S,HEINRICH E,LU J,et al.Epidermal growth factor receptor signaling to the mitogen activated protein kinase pathway bypasses ras in pancreatic cancer cells[J].Pancreas,2016,45(2):286-292.

[7]BOURNET B,MUSCARI F,BUSCAIL C,et al.KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma[J].Clin Transl Gastroenterol,2016.[Epub ahead of print].

[8]DING N,CUI XX,GAO Z,et al.A triple combination of atorvastatin,celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors[J].Int J Oncol,2014,44(6):2139-2145.

[9]MUSCARELLA P,WILFONG LS,ROSS SB,et al.A randomized,placebo controlled,double blind,multicenter phase 2 adjuvant trial of the efficacy,immunogeneicity,and safety of GI-4000 plus Gem vs.Gem alone in patients with resected pancreas cancer with activating Ras mutations/survival and immunology analysis of the R1 Subgroup[J].J Clin Oncol,2012,30:e14501.

[10]WANG JP,WU CY,YEH YC,et al.Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations:a randomized,open-label,prospective trial[J].Oncotarget,2015,6(20):18162-18173.

[11]LEE CC,SHIAO HY,WANG WC,et al.Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer[J].Expert Opin Investig Drugs,2014,23(10):1333-1348.

[12]PHILIP PA,BENEDETTI J,CORLESS CL,et al.PhaseⅢstudy comparing gemcitabine plus cetuximab vs.gemcitabine in patients with advanced pancreatic adenocarcinoma:Southwest oncology group—directed intergroup trial S0205[J].J Clin Oncol,2010,28(22):3605-3610.

[13]MOORE M,GOLDSTEIN D,HAMM J,et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,2007,25(15):1960-1966.

[14]NAMKUNG J,KWON W,CHOI Y,et al.Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value[J].J Gastroenterol Hepatol,2015.[Epub ahead of print].

[15]EL-RAYES BF,ZALIPSKI MM,SHIELDS AF,et al.A phaseⅡstudy of celecoxib,gemcitabine,and cisplatin in advanced pancreatic cancer[J].Investig New Drugs,2005,23(6):583-590.

[16]MUKHERJEE P,BASU GD,TINDER TL,et al.Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition[J].J Immunol,2009,182(1):216-224.

[17]RAO CV,JANAKIRAM NB,MADKA V,et al.Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma[J].Oncotarget,2015,6(32):33290-33305.

[18]MOHAMMED A,JANAKIRAM NB,MADKA V,et al.Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression[J].Oncotarget,2015,6(17):15524-15539.

[19]MOORE MJ,HAMM J,DANCEY J,et al.Comparison of gemcitabine vesus the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced or adenocarcinoma of the pancreas:a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,2003,21(2):3296-3300.

[20]TAI CJ,HUANG MT,WU CH,et al.Combination of two targeted medications(bevacizumab plus cetuximab)improve the therapeutic response of pancreatic carcinoma[J].Medicine(Baltimore),2016.[Epub ahead of print].

[21]YU Z,ZHONG W,TAN ZM,et al.Gemcitabine adjuvant therapy for resected pancreatic cancer:a meta-analysis[J].Am J Clin Oncol,2015,38(3):322-325.

[22]RENI M,CEREDA S,MILELLA M,et al.Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma:a phaseⅡrandomised trial[J].Eur J Cancer,2013,49(17):3609-3615.

施引文献

资源附件(0)

访问统计